Drugs / GSK610677
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00694902 | May → Sep 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK610677 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00694902 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL3544968 ↗ |
| Route | Inhaled | “Subjects will receive GSK610677 as single inhale dose.” NCT00694902 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL3544968 ↗ |